Antidopaminergic effects of the stereoisomers of N[(1-alkyl-2-pyrrolidinyl)methyl]-5-sulfamoylbenzamides and -2,3-dihydrobenzofuran-7-carboxamides

The stereoisomers of some N-[(1-alkyl-2-pyrrolidinyl)methyl]-5- sulfaoylbenzamides (3-8) and -2,3-dihydrobenzofuran-7-carboxamides (9-18) were prepared to compare their dopamine D2 receptor binding affinities (in vitro) and inhibitory effects on apomorphine-induced hyperactivity (in vivo). In the 1-...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 1991, Vol.34 (1), p.261-267
Hauptverfasser: MURAKAMI, S, MARUBAYASHI, N, FUKUDA, T, TAKEHARA, S, TAHARA, T
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 267
container_issue 1
container_start_page 261
container_title Journal of medicinal chemistry
container_volume 34
creator MURAKAMI, S
MARUBAYASHI, N
FUKUDA, T
TAKEHARA, S
TAHARA, T
description The stereoisomers of some N-[(1-alkyl-2-pyrrolidinyl)methyl]-5- sulfaoylbenzamides (3-8) and -2,3-dihydrobenzofuran-7-carboxamides (9-18) were prepared to compare their dopamine D2 receptor binding affinities (in vitro) and inhibitory effects on apomorphine-induced hyperactivity (in vivo). In the 1-ethyl substituted compounds of the two series, the stereoisomers with S absolute configuration at the 2-position of the pyrrolidine moiety (S enantiomer 3 and 2S diastereomers 9 and 10) were more potent in both of the above activities than those with R absolute configuration (R enantiomer 4 and 2R diastereomers 11 and 12, respectively), whereas the R enantiomer (8) was more potent than the S enantiomer (7) in the 1-n-hexyl-substituted-benzamides and the 2R diastereomers (15, 16, and 18) were more potent than the 2S diastereomers (13, 14, and 17) in the 1-n-butyl- and 1-n-hexyl-2,3-dihydrobenzofuran-7-carboxamides. It was found that the stereospecificity of the compound activities altered from the S configuration to the R configuration as the 1-alkyl side chain became longer in the two series. How these stereoisomers meet the configurational requirements to interact with the dopamine D2 receptors is also discussed.
doi_str_mv 10.1021/jm00105a041
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_80436003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80436003</sourcerecordid><originalsourceid>FETCH-LOGICAL-p236t-2a7352e69d1abb7be6caafcb62937d6df4674db9c48e629b4c6b40713376c6e63</originalsourceid><addsrcrecordid>eNpFkE1LHTEUhkNRrlfbVdfCbBQLTT1JZjJ3lnLRtiC6sSspl3yceKOZyZjMgNOf4S92Wi90deB9Hl44LyGfGXxjwNn5YwvAoFJQsg9kySoOtFxBuUeWAJxTLrk4IIc5PwKAYFwsyIKteMVYtSSvF93gbexV6ztMD94U6ByaIRfRFcMWizxgwuhzbDH9C2_uzxhV4WkKlNN-SikGb303hS8tDtsp_KYVzWNwqo1T0Nj9mast5kJ1tqD8q6DWbyeb4l8U3ZhUR2tqVNLx5d38SPadChk_7e4R-XV1ebf-Qa9vv_9cX1zTngs5UK5qUXGUjWVK61qjNEo5oyVvRG2ldaWsS6sbU65wznRppC6hZkLU0kiU4oicvvf2KT6PmIdN67PBEFSHccybeUIh58Vm8XgnjrpFu-mTb1WaNrsRZ36y4yobFdz8kvH5v9ZIqAEa8QaoooLY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80436003</pqid></control><display><type>article</type><title>Antidopaminergic effects of the stereoisomers of N[(1-alkyl-2-pyrrolidinyl)methyl]-5-sulfamoylbenzamides and -2,3-dihydrobenzofuran-7-carboxamides</title><source>ACS Publications</source><source>MEDLINE</source><creator>MURAKAMI, S ; MARUBAYASHI, N ; FUKUDA, T ; TAKEHARA, S ; TAHARA, T</creator><creatorcontrib>MURAKAMI, S ; MARUBAYASHI, N ; FUKUDA, T ; TAKEHARA, S ; TAHARA, T</creatorcontrib><description>The stereoisomers of some N-[(1-alkyl-2-pyrrolidinyl)methyl]-5- sulfaoylbenzamides (3-8) and -2,3-dihydrobenzofuran-7-carboxamides (9-18) were prepared to compare their dopamine D2 receptor binding affinities (in vitro) and inhibitory effects on apomorphine-induced hyperactivity (in vivo). In the 1-ethyl substituted compounds of the two series, the stereoisomers with S absolute configuration at the 2-position of the pyrrolidine moiety (S enantiomer 3 and 2S diastereomers 9 and 10) were more potent in both of the above activities than those with R absolute configuration (R enantiomer 4 and 2R diastereomers 11 and 12, respectively), whereas the R enantiomer (8) was more potent than the S enantiomer (7) in the 1-n-hexyl-substituted-benzamides and the 2R diastereomers (15, 16, and 18) were more potent than the 2S diastereomers (13, 14, and 17) in the 1-n-butyl- and 1-n-hexyl-2,3-dihydrobenzofuran-7-carboxamides. It was found that the stereospecificity of the compound activities altered from the S configuration to the R configuration as the 1-alkyl side chain became longer in the two series. How these stereoisomers meet the configurational requirements to interact with the dopamine D2 receptors is also discussed.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm00105a041</identifier><identifier>PMID: 1825115</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Animals ; Benzamides - chemical synthesis ; Benzamides - chemistry ; Benzamides - pharmacology ; Chemistry ; Corpus Striatum - metabolism ; Dopamine Antagonists ; Exact sciences and technology ; Heterocyclic compounds ; Heterocyclic compounds with n hetero atom and also o and/or s, se, te hetero atoms ; Indicators and Reagents ; Molecular Conformation ; Molecular Structure ; Motor Activity - drug effects ; Optical Rotation ; Organic chemistry ; Preparations and properties ; Rats ; Receptors, Dopamine - drug effects ; Receptors, Dopamine - metabolism ; Receptors, Dopamine D2 ; Spiperone - metabolism ; Stereoisomerism ; Structure-Activity Relationship</subject><ispartof>Journal of medicinal chemistry, 1991, Vol.34 (1), p.261-267</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19607009$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1825115$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MURAKAMI, S</creatorcontrib><creatorcontrib>MARUBAYASHI, N</creatorcontrib><creatorcontrib>FUKUDA, T</creatorcontrib><creatorcontrib>TAKEHARA, S</creatorcontrib><creatorcontrib>TAHARA, T</creatorcontrib><title>Antidopaminergic effects of the stereoisomers of N[(1-alkyl-2-pyrrolidinyl)methyl]-5-sulfamoylbenzamides and -2,3-dihydrobenzofuran-7-carboxamides</title><title>Journal of medicinal chemistry</title><addtitle>J Med Chem</addtitle><description>The stereoisomers of some N-[(1-alkyl-2-pyrrolidinyl)methyl]-5- sulfaoylbenzamides (3-8) and -2,3-dihydrobenzofuran-7-carboxamides (9-18) were prepared to compare their dopamine D2 receptor binding affinities (in vitro) and inhibitory effects on apomorphine-induced hyperactivity (in vivo). In the 1-ethyl substituted compounds of the two series, the stereoisomers with S absolute configuration at the 2-position of the pyrrolidine moiety (S enantiomer 3 and 2S diastereomers 9 and 10) were more potent in both of the above activities than those with R absolute configuration (R enantiomer 4 and 2R diastereomers 11 and 12, respectively), whereas the R enantiomer (8) was more potent than the S enantiomer (7) in the 1-n-hexyl-substituted-benzamides and the 2R diastereomers (15, 16, and 18) were more potent than the 2S diastereomers (13, 14, and 17) in the 1-n-butyl- and 1-n-hexyl-2,3-dihydrobenzofuran-7-carboxamides. It was found that the stereospecificity of the compound activities altered from the S configuration to the R configuration as the 1-alkyl side chain became longer in the two series. How these stereoisomers meet the configurational requirements to interact with the dopamine D2 receptors is also discussed.</description><subject>Animals</subject><subject>Benzamides - chemical synthesis</subject><subject>Benzamides - chemistry</subject><subject>Benzamides - pharmacology</subject><subject>Chemistry</subject><subject>Corpus Striatum - metabolism</subject><subject>Dopamine Antagonists</subject><subject>Exact sciences and technology</subject><subject>Heterocyclic compounds</subject><subject>Heterocyclic compounds with n hetero atom and also o and/or s, se, te hetero atoms</subject><subject>Indicators and Reagents</subject><subject>Molecular Conformation</subject><subject>Molecular Structure</subject><subject>Motor Activity - drug effects</subject><subject>Optical Rotation</subject><subject>Organic chemistry</subject><subject>Preparations and properties</subject><subject>Rats</subject><subject>Receptors, Dopamine - drug effects</subject><subject>Receptors, Dopamine - metabolism</subject><subject>Receptors, Dopamine D2</subject><subject>Spiperone - metabolism</subject><subject>Stereoisomerism</subject><subject>Structure-Activity Relationship</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LHTEUhkNRrlfbVdfCbBQLTT1JZjJ3lnLRtiC6sSspl3yceKOZyZjMgNOf4S92Wi90deB9Hl44LyGfGXxjwNn5YwvAoFJQsg9kySoOtFxBuUeWAJxTLrk4IIc5PwKAYFwsyIKteMVYtSSvF93gbexV6ztMD94U6ByaIRfRFcMWizxgwuhzbDH9C2_uzxhV4WkKlNN-SikGb303hS8tDtsp_KYVzWNwqo1T0Nj9mast5kJ1tqD8q6DWbyeb4l8U3ZhUR2tqVNLx5d38SPadChk_7e4R-XV1ebf-Qa9vv_9cX1zTngs5UK5qUXGUjWVK61qjNEo5oyVvRG2ldaWsS6sbU65wznRppC6hZkLU0kiU4oicvvf2KT6PmIdN67PBEFSHccybeUIh58Vm8XgnjrpFu-mTb1WaNrsRZ36y4yobFdz8kvH5v9ZIqAEa8QaoooLY</recordid><startdate>1991</startdate><enddate>1991</enddate><creator>MURAKAMI, S</creator><creator>MARUBAYASHI, N</creator><creator>FUKUDA, T</creator><creator>TAKEHARA, S</creator><creator>TAHARA, T</creator><general>American Chemical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>1991</creationdate><title>Antidopaminergic effects of the stereoisomers of N[(1-alkyl-2-pyrrolidinyl)methyl]-5-sulfamoylbenzamides and -2,3-dihydrobenzofuran-7-carboxamides</title><author>MURAKAMI, S ; MARUBAYASHI, N ; FUKUDA, T ; TAKEHARA, S ; TAHARA, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p236t-2a7352e69d1abb7be6caafcb62937d6df4674db9c48e629b4c6b40713376c6e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Animals</topic><topic>Benzamides - chemical synthesis</topic><topic>Benzamides - chemistry</topic><topic>Benzamides - pharmacology</topic><topic>Chemistry</topic><topic>Corpus Striatum - metabolism</topic><topic>Dopamine Antagonists</topic><topic>Exact sciences and technology</topic><topic>Heterocyclic compounds</topic><topic>Heterocyclic compounds with n hetero atom and also o and/or s, se, te hetero atoms</topic><topic>Indicators and Reagents</topic><topic>Molecular Conformation</topic><topic>Molecular Structure</topic><topic>Motor Activity - drug effects</topic><topic>Optical Rotation</topic><topic>Organic chemistry</topic><topic>Preparations and properties</topic><topic>Rats</topic><topic>Receptors, Dopamine - drug effects</topic><topic>Receptors, Dopamine - metabolism</topic><topic>Receptors, Dopamine D2</topic><topic>Spiperone - metabolism</topic><topic>Stereoisomerism</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MURAKAMI, S</creatorcontrib><creatorcontrib>MARUBAYASHI, N</creatorcontrib><creatorcontrib>FUKUDA, T</creatorcontrib><creatorcontrib>TAKEHARA, S</creatorcontrib><creatorcontrib>TAHARA, T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MURAKAMI, S</au><au>MARUBAYASHI, N</au><au>FUKUDA, T</au><au>TAKEHARA, S</au><au>TAHARA, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antidopaminergic effects of the stereoisomers of N[(1-alkyl-2-pyrrolidinyl)methyl]-5-sulfamoylbenzamides and -2,3-dihydrobenzofuran-7-carboxamides</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J Med Chem</addtitle><date>1991</date><risdate>1991</risdate><volume>34</volume><issue>1</issue><spage>261</spage><epage>267</epage><pages>261-267</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>The stereoisomers of some N-[(1-alkyl-2-pyrrolidinyl)methyl]-5- sulfaoylbenzamides (3-8) and -2,3-dihydrobenzofuran-7-carboxamides (9-18) were prepared to compare their dopamine D2 receptor binding affinities (in vitro) and inhibitory effects on apomorphine-induced hyperactivity (in vivo). In the 1-ethyl substituted compounds of the two series, the stereoisomers with S absolute configuration at the 2-position of the pyrrolidine moiety (S enantiomer 3 and 2S diastereomers 9 and 10) were more potent in both of the above activities than those with R absolute configuration (R enantiomer 4 and 2R diastereomers 11 and 12, respectively), whereas the R enantiomer (8) was more potent than the S enantiomer (7) in the 1-n-hexyl-substituted-benzamides and the 2R diastereomers (15, 16, and 18) were more potent than the 2S diastereomers (13, 14, and 17) in the 1-n-butyl- and 1-n-hexyl-2,3-dihydrobenzofuran-7-carboxamides. It was found that the stereospecificity of the compound activities altered from the S configuration to the R configuration as the 1-alkyl side chain became longer in the two series. How these stereoisomers meet the configurational requirements to interact with the dopamine D2 receptors is also discussed.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>1825115</pmid><doi>10.1021/jm00105a041</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 1991, Vol.34 (1), p.261-267
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_80436003
source ACS Publications; MEDLINE
subjects Animals
Benzamides - chemical synthesis
Benzamides - chemistry
Benzamides - pharmacology
Chemistry
Corpus Striatum - metabolism
Dopamine Antagonists
Exact sciences and technology
Heterocyclic compounds
Heterocyclic compounds with n hetero atom and also o and/or s, se, te hetero atoms
Indicators and Reagents
Molecular Conformation
Molecular Structure
Motor Activity - drug effects
Optical Rotation
Organic chemistry
Preparations and properties
Rats
Receptors, Dopamine - drug effects
Receptors, Dopamine - metabolism
Receptors, Dopamine D2
Spiperone - metabolism
Stereoisomerism
Structure-Activity Relationship
title Antidopaminergic effects of the stereoisomers of N[(1-alkyl-2-pyrrolidinyl)methyl]-5-sulfamoylbenzamides and -2,3-dihydrobenzofuran-7-carboxamides
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T04%3A58%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antidopaminergic%20effects%20of%20the%20stereoisomers%20of%20N%5B(1-alkyl-2-pyrrolidinyl)methyl%5D-5-sulfamoylbenzamides%20and%20-2,3-dihydrobenzofuran-7-carboxamides&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=MURAKAMI,%20S&rft.date=1991&rft.volume=34&rft.issue=1&rft.spage=261&rft.epage=267&rft.pages=261-267&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm00105a041&rft_dat=%3Cproquest_pubme%3E80436003%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80436003&rft_id=info:pmid/1825115&rfr_iscdi=true